XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.75 and traded as high as $3.01. XTL Biopharmaceuticals shares last traded at $2.98, with a volume of 40,707 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

XTL Biopharmaceuticals Stock Up 0.7%

The firm’s 50-day simple moving average is $2.77 and its 200 day simple moving average is $2.78. The firm has a market cap of $6.12 million, a P/E ratio of -4.34 and a beta of 1.46.

XTL Biopharmaceuticals (NASDAQ:XTLB) last released its earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of ($0.26) million during the quarter.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.